

Regulatory Affairs

PLUVICTO
(lutetium (¹⁷⁷Lu) vipivotide tetraxetan)

1 GBq/mL (1 000 MBq/mL) solution for injection/infusion

Malaysia Package Leaflet
(CDS v2.02;
VISION - EU approved 16-Jun-2025,
PSMAfore - US approved 28-Mar-2025)

Effective date: ~~19-Aug-2024~~7-Apr-2025

Safety Label Change
(SLC) Tracking Number: ~~2024-PSB/GLC-1429-sNA~~

Document status: Final

Property of Novartis
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Novartis

1. NAME OF THE MEDICINAL PRODUCT

Pluvicto 1 000 MBq/mL solution for injection/infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One mL of solution contains 1 000 MBq of lutetium (^{177}Lu) vipivotide tetraxetan at the date and time of calibration.

The total amount of radioactivity per single-dose vial is 7 400 MBq $\pm$ 10% at the date and time of administration. Given the fixed volumetric activity of 1 000 MBq/mL at the date and time of calibration, the volume of the solution in the vial can range from 7.5 mL to 12.5 mL in order to provide the required amount of radioactivity at the date and time of administration.

Physical characteristics

Lutetium-177 decays to a stable hafnium-177 with a physical half-life of 6.647 days by emitting beta-minus radiation with a maximum energy of ~~0.498~~ 0.498 ~~kMeV~~ MeV (79%) and photon radiation (γ) of ~~0.208~~ 0.208 ~~kMeV~~ MeV (11%) and ~~0.113~~ 0.113 ~~kMeV~~ MeV (6.4%).

Excipient with known effect

Each mL of solution contains up to 0.312 mmol (7.1 mg) of sodium. Each vial contains up to 88.75 mg of sodium.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for injection/infusion.

Clear, colourless to slightly yellow solution, pH: 4.5 to 7.0.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and

- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy.

Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy (see section 5.1).

Commented [KL1]: Unit updated to align with CDS.

Commented [KL2]: New indication wordings fully aligned to US PI

4.2 Posology and method of administration

Important safety instructions

Pluvicto should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings (see section 6.5) and after evaluation of the patient by a qualified physician.

Radiopharmaceuticals, including Pluvicto, should be used by or under the control of healthcare professionals who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorised to license the use of radiopharmaceuticals.

Patient identification

Patients should be identified for treatment by PSMA imaging.

Posology

The recommended treatment regimen of Pluvicto is 7 400 MBq intravenously every 6 weeks (±1 week) for ~~up to~~ a total of 6 doses, unless there is disease progression or unacceptable toxicity.

Commented [KL3]: Updated to align with CDS and USPI

Medical castration with a gonadotropin-releasing hormone (GnRH) analogue should be continued during treatment in patients not surgically castrated.

Treatment monitoring

Laboratory tests should be performed before and during treatment with Pluvicto. Dosing may need to be modified based on the test results (see Table 1).

- Haematology (haemoglobin, white blood cell count, absolute neutrophil count, platelet count)
- Kidney function (serum creatinine, calculated creatinine clearance [CLcr])
- Liver function (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, blood serum albumin, total blood bilirubin)

Dose modifications for adverse reactions

Recommended dose modifications of Pluvicto for adverse reactions are provided in Table 1. Management of severe or intolerable adverse reactions may require temporary dose interruption, dose reduction or permanent discontinuation of treatment with Pluvicto. If a treatment delay due to an adverse reaction persists for >4 weeks, treatment ~~discontinuation~~ with Pluvicto ~~must may~~ be ~~discontinued~~ ~~considered~~. The dose of Pluvicto may be reduced by 20% to 5 900 MBq once; the dose should not be re-escalated. If a patient has further adverse reactions that would require an additional dose reduction, treatment with Pluvicto must be discontinued.

Commented [KL4]: Updated to align with CDS and USPI

Table 1 Recommended dose modifications of Pluvicto for adverse reactions

Adverse reaction	Severity ^a	Dose modification
Dry mouth	Grade 3	Reduce Pluvicto dose by 20% to 5 900 MBq.
Gastrointestinal toxicity	Grade ≥ 3 (not amenable to medical intervention)	Withhold Pluvicto until improvement to grade 2 or baseline. Reduce Pluvicto dose by 20% to 5 900 MBq.
Myelosuppression (anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia)	Grade 2	Withhold Pluvicto until improvement to grade 1 or baseline. Manage as deemed appropriate. The use of growth factors is permitted but should be discontinued once improved to grade 1 or baseline. Checking haematinic levels (iron, B12 and folate) and providing supplementation is advocated. Transfusions may be given as clinically indicated.
	Grade ≥ 3	Withhold Pluvicto until improvement to grade 1 or baseline. Reduce Pluvicto dose by 20% to 5 900 MBq.
Renal toxicity	Defined as: - Confirmed serum creatinine increase (grade ≥ 2) - Confirmed CLcr <50-30 mL/min; calculate using CockcroftGault with actual body weight	Withhold Pluvicto until improvement.
	Defined as: - Confirmed $\geq 40\%$ increase from baseline serum creatinine <u>and</u> - Confirmed $>40\%$ decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weight	Withhold Pluvicto until improvement or return to baseline. Reduce Pluvicto dose by 20% to 5 900 MBq.
	Recurrent renal toxicity (grade ≥ 3)	Permanently discontinue Pluvicto.
Spinal cord compression	Any	Withhold Pluvicto until the compression has been adequately treated and any neurological sequela have stabilised and ECOG performance status has stabilised.
Fracture in weight-bearing bones	Any	Withhold Pluvicto until the fracture has been adequately stabilised/treated and ECOG performance status has stabilised.
Fatigue	Grade ≥ 3	Withhold Pluvicto until improvement to Grade 2 or baseline.
Electrolyte or metabolic abnormalities	Grade ≥ 2	Withhold Pluvicto until improvement to Grade 1 or baseline.

Commented [KL5]: Updated to align with CDS and USPI

Non-haematological toxicity (clinically significant, not otherwise stated)	Grade ≥ 2	Withhold Pluvicto until improvement to Grade 1 or baseline.
AST or ALT elevation	AST or ALT > 5 times ULN in the absence of liver metastases	Permanently discontinue Pluvicto.
Abbreviations: CLcr, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal. Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE). ^a The same thresholds are also applicable to baseline values at the time of treatment initiation with Pluvicto.		

Commented [KL6]: Updated to align with CDS. To refer CDS 2.1

Special populations

Elderly

No dose adjustment is recommended in patients aged 65 years or older.

Renal impairment

No dose adjustment is recommended for patients with mild to moderate renal impairment with baseline CLcr ≥ 30 mL/min by Cockcroft-Gault. Treatment with Pluvicto is not recommended in patients with moderate to severe renal impairment with baseline CLcr < 30 mL/min or end-stage renal disease as the pharmacokinetic profile and safety of Pluvicto have not been studied in these patients (see sections 4.4 and 5.2).

Hepatic impairment

No dose adjustment is recommended for patients with hepatic impairment. Pluvicto has not been studied in patients with moderate or severe hepatic impairment (see section 5.2).

Paediatric population

There is no relevant use of Pluvicto in the paediatric population in the indication of treatment of PSMA-expressing prostate cancer.

Method of administration

Pluvicto is a ready-to-use solution for injection/infusion for single use only.

Administration instructions

The recommended dose of Pluvicto may be administered intravenously as an injection using the syringe method, as an infusion using the gravity method, or as an infusion using the peristaltic pump method.

When using the gravity or peristaltic pump method, Pluvicto should be infused directly from its original container.

The syringe method or the peristaltic pump method should be used when administering a reduced dose of Pluvicto following a dose modification for an adverse reaction. When using the gravity method for a reduced dose, the Pluvicto dose should be adjusted before the administration to avoid the delivery of an incorrect volume of Pluvicto.

Prior to administration, the intravenous catheter used exclusively for Pluvicto administration should be flushed with ≥ 10 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection to ensure patency and to minimise the risk of extravasation. Cases of extravasation should be managed as per institutional guidelines. Patients should be advised to remain well hydrated and to urinate frequently before and after administration of Pluvicto (see section 4.4).

For instructions on the method of preparation and intravenous methods of administration, see section 12.

For patient preparation, see section 4.4.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Individual benefit/risk justification

For each patient, the radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required therapeutic effect.

Risk from radiation exposure

Pluvicto contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

Radiation exposure to patients, medical personnel, and others should be minimised during and after treatment with Pluvicto consistent with institutional good radiation safety practices, patient management procedures, and instructions to the patient for follow-up radiation protection at home.

Patient preparation

Patients should be encouraged to increase oral fluids and urged to void as often as possible to reduce bladder radiation, especially after high activities, e.g. for radionuclide therapy.

After the procedure

Before the patient is released, the nuclear medicine physician or healthcare professional should explain the necessary radioprotection precautions that the patient should follow to minimise radiation exposure to others.

After each administration of Pluvicto, the following general recommendations for patients can be considered along with national, local and institutional procedures and regulations.

- Limit close contact (less than 1 metre) with others for 2 days or with children and pregnant women for 7 days.
- Refrain from sexual activity for 7 days.
- Sleep in a separate room from others for 3 days, from children for 7 days, or from pregnant women for 15 days.

Myelosuppression

In the PSMAfore study, myelosuppression occurred more frequently in patients who received Pluvicto compared to patients who switched to another ARPI therapy (see section 4.8).

In the VISION study, myelosuppression, including fatal cases, occurred more frequently in patients who received Pluvicto plus best standard of care (BSoC) compared to patients who received BSoC alone (see section 4.8).

Haematology laboratory tests, including haemoglobin, white blood cell count, absolute neutrophil count and platelet count, should be performed before and during treatment with Pluvicto. Pluvicto

Commented [KL7]: Updated to align with CDS

should be withheld, dose reduced or permanently discontinued and patients should be clinically managed as deemed appropriate based on the severity of myelosuppression (see section 4.2).

Renal toxicity

In the PSMAfore study, renal toxicity was comparable in patients who received Pluvicto compared to patients who switched to another ARPI therapy (see section 4.8).

Commented [KL8]: Updated to align with CDS

In the VISION study, renal toxicity occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (see section 4.8).

Before and after administration of Pluvicto, patients should be encouraged to increase oral fluids and urged to void as often as possible, especially after high activities, e.g. for radionuclide therapy. Kidney function laboratory tests, including serum creatinine and calculated CLcr, should be performed before and during treatment with Pluvicto. Pluvicto should be withheld, dose reduced or permanently discontinued based on the severity of renal toxicity (see section 4.2).

Renal/Hepatic impairment

Careful consideration of the benefit risk ratio in these patients is required since an increased radiation exposure is possible.

Exposure (AUC) of lutetium (^{177}Lu) vipivotide tetraxetan is expected to increase with the degree of renal impairment (see section 5.2). Patients with mild or moderate renal impairment may be at greater risk of toxicity. Renal function and adverse reactions should be frequently monitored in patients with mild to moderate renal impairment (see section 4.2). Treatment with Pluvicto is not recommended in patients with moderate to severe renal impairment with baseline CLcr <50 mL/min or end-stage renal disease.

Fertility

Radiations of lutetium (^{177}Lu) vipivotide tetraxetan may potentially have toxic effects on male gonads and spermatogenesis. The recommended cumulative dose of 44 400 MBq of Pluvicto results in a radiation absorbed dose to the testes within the range where Pluvicto may cause infertility. Genetic consultation is recommended if the patient wishes to have children after treatment. Cryopreservation of sperm can be discussed as an option for male patients before treatment (see section 4.6).

Contraception in males

Male patients are advised not to father a child and to use a condom for intercourse during treatment with Pluvicto and for 14 weeks after the last dose (see section 4.6).

Specific warnings

Sodium content

This medicinal product contains up to 3.9 mmol (88.75 mg) sodium per vial, equivalent to 4.4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

Precautions with respect to environmental hazard see section 6.5.

4.5 Interaction with other medicinal products and other forms of interaction

No clinical drug interaction studies were performed.

4.6 Fertility, pregnancy and lactation

Contraception in males

Because of potential effects on spermatogenesis associated with radiations of lutetium (^{177}Lu) vipivotide tetraxetan, male patients are advised not to father a child and to use a condom for intercourse during treatment with Pluvicto and for 14 weeks after the last dose (see section 4.4).

Pregnancy

Pluvicto is not indicated for use in females. No animal studies using lutetium (^{177}Lu) vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-foetal development. However, all radioactive emissions, including those from Pluvicto, can cause foetal harm when administered to a pregnant woman.

Breast-feeding

Pluvicto is not indicated for use in females. There are no data on the presence of lutetium (^{177}Lu) vipivotide tetraxetan in human milk or its effects on the breast-fed newborn/infant or on milk production.

Fertility

No studies were conducted to determine the effects of lutetium (^{177}Lu) vipivotide tetraxetan on fertility. Radiations of lutetium (^{177}Lu) vipivotide tetraxetan may potentially have toxic effects on male gonads and spermatogenesis. The recommended cumulative dose of 44 400 MBq of Pluvicto results in a radiation absorbed dose to the testes within the range where Pluvicto may cause infertility. Genetic consultation is recommended if the patient wishes to have children after treatment. Cryopreservation of sperm can be discussed as an option for male patients before treatment (see section 4.4).

4.7 Effects on ability to drive and use machines

Pluvicto may have a minor influence on the ability to drive and use machines.

4.8 Undesirable effects

Commented [KL9]: Updated to align with CDS

PSMAfore

Summary of the safety profile

The safety of Pluvicto was evaluated in the Phase III PSMAfore study in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy. Of the 468 patients randomized, 459 patients received at least one dose of randomized treatment. Patients received either Pluvicto 7.4 GBq (7,400 MBq) (200 mCi) administered every 6 weeks (N = 227) or a change in ARPI (N = 232).

Among patients who received Pluvicto, the median number of doses of Pluvicto received was 6 (range: 1 to 6), with 63.4% of patients who received all 6 doses of Pluvicto. The median cumulative dose of Pluvicto was 42.4 GBq 42,400 MBq (range: 7.0 to 45.4) (42,400 MBq) (range: 7,000 to 45,400). The median duration of exposure to randomized treatment was 8.4 months (range: 0.4 to 11.6) for patients who received Pluvicto and 6.5 months (range: 0.03 to 29.2) for patients who received a change in ARPI. The data analyses presented below do not include patients who crossed over to receive Pluvicto after receiving treatment in the change in ARPI arm.

Table 2 summarizes the incidence of adverse drug reactions. The most common adverse drug reactions ($\geq 20\%$) in patients who received Pluvicto include: dry mouth (60.8%), fatigue (52.9%), nausea (31.7%), anaemia (27.3%), constipation (22.0%) and decreased appetite (21.6%). The most common Grade 3 to 4 adverse drug reactions ($\geq 5\%$) in patients who received Pluvicto include: anaemia (6.2%).

Tabulated summary of adverse drug reactions

Adverse drug reactions (Table 2) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$).

Table 2 Adverse drug reactions in patients who received Pluvicto compared to a change in ARPI in PSMAfore^a

Adverse drug reactions	Pluvicto* (N = 227)			Change in ARPI (N = 232)		
	All grades n (%)	Frequency category	Grades 3 to 4 ^b n (%)	All grades n (%)	Frequency category	Grades 3 to 4 ^b n (%)
Infections and infestations						
Urinary tract infection ^c	13 (5.7%)	Common	3 (1.3%)	18 (7.8%)	Common	7 (3.0%)
Oral fungal infection ^d	7 (3.1%)	Common	0	2 (0.9%)	Uncommon	0
Blood and lymphatic system disorders						
Anaemia	62 (27.3%)	Very common	14 (6.2%)	45 (19.4%)	Very common	16 (6.9%)
Leukopenia ^e	25 (11.0%)	Very common	5 (2.2%)	6 (2.6%)	Common	2 (0.9%)
Thrombocytopenia	23 (10.1%)	Very common	7 (3.1%)	9 (3.9%)	Common	2 (0.9%)
Lymphopenia	15 (6.6%)	Common	10 (4.4%)	3 (1.3%)	Common	1 (0.4%)
Pancytopenia	1 (0.4%)	Uncommon	0	1 (0.4%)	Uncommon	0
Metabolism and nutrition disorders						
Decreased appetite	49 (21.6%)	Very common	0	43 (18.5%)	Very common	1 (0.4%)
Nervous system disorders						
Dysgeusia ^f	20 (8.8%)	Common	0	7 (3.0%)	Common	0
Headache	19 (8.4%)	Common	0	11 (4.7%)	Common	0
Dizziness	10 (4.4%)	Common	0	13 (5.6%)	Common	0
Eye disorders						
Dry eye ^g	14 (6.2%)	Common	0	2 (0.9%)	Uncommon	0
Ear and labyrinth disorders						
Vertigo	4 (1.8%)	Common	0	3 (1.3%)	Common	0
Gastrointestinal disorders						
Dry mouth ^h	138 (60.8%)	Very common	2 (0.9%)	6 (2.6%)	Common	0
Nausea	72 (31.7%)	Very common	0	27 (11.6%)	Very common	1 (0.4%)
Constipation	50 (22.0%)	Very common	1 (0.4%)	33 (14.2%)	Very common	0
Diarrhoea	38 (16.7%)	Very common	0	21 (9.1%)	Common	1 (0.4%)
Vomiting	26 (11.5%)	Very common	0	11 (4.7%)	Common	0
Abdominal pain ⁱ	21 (9.3%)	Common	2 (0.9%)	19 (8.2%)	Common	1 (0.4%)
Oesophageal disorder ^j	9 (4.0%)	Common	1 (0.4%)	2 (0.9%)	Uncommon	0
Stomatitis	3 (1.3%)	Common	1 (0.4%)	2 (0.9%)	Uncommon	0

<u>Adverse drug reactions</u>	<u>Pluvicto*</u> (N = 227)			<u>Change in ARPI</u> (N = 232)		
	<u>All grades n (%)</u>	<u>Frequency category</u>	<u>Grades 3 to 4^b n (%)</u>	<u>All grades n (%)</u>	<u>Frequency category</u>	<u>Grades 3 to 4^b n (%)</u>
<u>Skin and subcutaneous tissue disorders</u>						
<u>Dry skin^k</u>	9 (4.0%)	Common	0	5 (2.2%)	Common	0
<u>Renal and urinary disorders</u>						
<u>Acute kidney injury^l</u>	15 (6.6%)	Common	3 (1.3%)	18 (7.8%)	Common	7 (3.0%)
<u>General disorders and administration site conditions</u>						
<u>Fatigue^m</u>	120 (52.9%)	Very common	3 (1.3%)	124 (53.4%)	Very common	12 (5.2%)
<u>Oedema peripheral</u>	19 (8.4%)	Common	0	28 (12.1%)	Very common	0
<u>Pyrexia</u>	6 (2.6%)	Common	1 (0.4%)	10 (4.3%)	Common	0
<u>Investigations</u>						
<u>Weight decreased</u>	15 (6.6%)	Common	1 (0.4%)	32 (13.8)	Very common	3 (1.3%)

Abbreviation: ARPI, androgen receptor pathway inhibitor.

**Patients in the Pluvicto arm do not include patients who crossed over to receive Pluvicto after receiving treatment in the change in ARPI arm.*

^aNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

^bOnly includes Grades 3 to 4 adverse drug reactions, no grade 5 adverse drug reactions recorded during treatment phase.

^cUrinary tract infection includes urinary tract infection, cystitis, and urinary tract infection enterococcal.

^dOral fungal infection includes candida infection, oral candidiasis, oral fungal infection, and oropharyngeal candidiasis.

^eLeukopenia includes neutropenia and leukopenia.

^fDysgeusia includes dysgeusia and taste disorder.

^gDry eye includes dry eye and xerophthalmia.

^hDry mouth includes dry mouth, mucosal dryness, salivary hyposecretion, dry throat, and lip dry.

ⁱAbdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, and epigastric discomfort.

^jOesophageal disorder includes gastrooesophageal reflux disease, dysphagia, oesophagitis, and burn oesophageal.

^kDry skin includes xerosis and dry skin.

^lAcute kidney injury includes blood creatinine increased, acute kidney injury, renal failure, and blood urea increased.

^mFatigue includes asthenia and fatigue.

Description of selected adverse drug reactions

Myelosuppression

In the PSMAfore study, myelosuppression occurred more frequently in patients who received Pluvicto compared to patients who received a change in ARPI (all Grades/Grade ≥3): anaemia (26.9%/6.2%) versus (19.0%/6.9%); thrombocytopenia (7.5%/2.2%) versus (3.0%/0.9%); neutropenia (5.7%/1.3%) versus (0.9%/0.4%); leukopenia (2.2%/0.9%) versus (0%/0%); lymphopenia (1.8%/0.4%) versus (0%/0%); and pancytopenia (0.4%/0%) versus (0.4%/0%). One fatal case of bone marrow failure occurred during the long term follow-up period in a patient treated with Pluvicto.

Myelosuppression adverse drug reactions that led to permanent discontinuation in >0.5% of patients who received Pluvicto included: thrombocytopenia (1.3%). Myelosuppression adverse drug reactions that led to dose interruptions /dose reductions in ≥0.5% of patients who received Pluvicto included: anaemia (1.8%/0.4%) and neutropenia (0.9%/0.4%).

Renal toxicity

In the PSMAfore study, renal toxicity was comparable in patients who received Pluvicto compared to patients who received a change in ARPI (all Grades/Grade 3 to 4): blood creatinine increased (4.4%/0%) versus (3.0%/0%); acute kidney injury (2.2%/1.3%) versus (3.9%/2.2%); renal failure (0.9%/0.4%) versus (1.3%/0.9%); and blood urea increased (0.4%/0%) versus (0%/0%).

Renal adverse drug reactions that led to permanent discontinuation in >0.4% of patients who received Pluvicto included: acute kidney injury (0.4%). Renal adverse drug reactions that led to dose interruptions /dose reductions in >0.4% of patients who received Pluvicto included: blood creatinine increased (0.4%/0%) and renal failure (0.4%/0%).

VISION

Summary of safety profile

Unless otherwise stated, the frequency of listed adverse reactions is based on data from the VISION study in which 529 patients received at least one dose of 7 400 MBq (median number of doses was five).

The most common adverse reactions include: fatigue (48.0%), dry mouth (39.3%), nausea (35.7%), anaemia (31.9%), decreased appetite (21.4%) and constipation (20.2%). The most common grade 3 to 4 adverse reactions include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%) and fatigue (6.6%).

At the time of VISION final analysis, after a median follow-up duration of 14.2 months (range: 0.6 to 60.9 months), the overall safety profile remained consistent with that previously reported.

Tabulated list of adverse reactions

Adverse reactions (Table 23) are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse reaction is based on the following convention (CIOMS III): very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1\,000$ to $< 1/100$); rare ($\geq 1/10\,000$ to $< 1/1\,000$); very rare ($< 1/10\,000$).

Summary of the safety profile

The safety of Pluvicto was evaluated in the Phase III VISION study in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy and taxane-based chemotherapy. Of the 831 patients randomized, 734 patients received at least one dose of randomized treatment. Patients received at least one dose of either Pluvicto 7,400 MBq (200 mCi) administered every 6 weeks plus BSoC (N = 529) or BSoC alone (N = 205).

Among patients who received Pluvicto plus BSoC, the median number of doses of Pluvicto received was 5 (range: 1 to 6), with 67.7% of patients who received at least 4 doses of Pluvicto and 46.5% of patients who received a total of 6 doses of Pluvicto. The median cumulative dose of Pluvicto was 37,500 MBq (range: 7.0 to 48.3) (range: 7,000 to 48,300). The median duration of exposure to randomized treatment was 7.8 months (range: 0.3 to 36.5) for patients who received Pluvicto plus BSoC and 2.1 months (range: 0.0 to 34.0) for patients who received BSoC alone.

Table 3 summarizes the incidence of adverse drug reactions. The most common adverse drug reactions ($\geq 20\%$) in patients who received Pluvicto include: fatigue (48.0%), dry mouth (39.3%), nausea (35.7%), anaemia (31.9%), decreased appetite (21.4%), and constipation (20.2%). The most common Grade 3 to 4 adverse drug reactions ($\geq 5\%$) in patients who received Pluvicto include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%), and fatigue (6.6%).

Tabulated summary of adverse drug reactions

Adverse drug reactions (Table 3) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$).

Table 23 Adverse reactions occurring at a higher incidence in patients who received Pluvicto plus BSoC compared to BSoC alone in VISION^a

System organ class Adverse reaction	Frequency category	All grades n (%)	Grades 3 to 4 ^b n (%)
Infections and infestations			
Oral fungal infection ^c	Common	13 (2.5)	0 (0.0)
Blood and lymphatic system disorders			
Anaemia	Very common	169 (31.9)	68 (12.9)
Thrombocytopenia	Very common	91 (17.2)	42 (7.9)
Leukopenia ^d	Very common	83 (15.7)	22 (4.2)
Lymphopenia	Very common	75 (14.2)	41 (7.8)
Panecytopenia ^e	Common	9 (1.7)	7 (1.3) ^b
Bone marrow failure	Uncommon	1 (0.2)	1 (0.2) ^b
Nervous system disorders			
Dizziness	Common	44 (8.3)	5 (0.9)
Headache	Common	37 (7.0)	4 (0.8)
Dysgeusia ^f	Common	37 (7.0)	0 (0.0)
Eye disorders			
Dry eye	Common	16 (3.0)	0 (0.0)
Ear and labyrinth disorders			
Vertigo	Common	11 (2.1)	0 (0.0)
Gastrointestinal disorders			
Dry mouth ^g	Very common	208 (39.3)	0 (0.0)
Nausea	Very common	189 (35.7)	7 (1.3)
Constipation	Very common	107 (20.2)	6 (1.1)
Vomiting ^h	Very common	101 (19.1)	5 (0.9)
Diarrhoea	Very common	101 (19.1)	4 (0.8)
Abdominal pain ⁱ	Very common	61 (11.5)	7 (1.3)
Oesophageal disorder ^j	Common	18 (3.4)	1 (0.2)
Stomatitis	Common	9 (1.7)	1 (0.2)
Skin and subcutaneous tissue disorders			
Dry skin ^k	Common	8 (1.5)	0 (0.0)
Renal and urinary disorders			
Urinary tract infection ^l	Very common	63 (11.9)	20 (3.8)
Acute kidney injury ^m	Common	48 (9.1)	18 (3.4)

General disorders and administration site conditions			
Fatigue ^a	Very common	254 (48.0)	35 (6.6)
Decreased appetite	Very common	113 (21.4)	10 (1.9)
Weight decreased	Very common	58 (11.0)	2 (0.4)
Oedema peripheral ^a	Very common	53 (10.0)	2 (0.4)
Pyrexia	Common	37 (7.0)	2 (0.4)

Abbreviation: BSoC, best standard of care.

^a—National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

^b—Only includes grades 3 to 4 adverse reactions, with the exception of pancytopenia and bone marrow failure. Grade 5 (fatal) pancytopenia was reported in 2 patients who received Pluvicto plus BSoC. Grade 5 (fatal) bone marrow failure was reported in 1 patient who received Pluvicto plus BSoC.

^c—Oral fungal infection includes oral candidiasis, candida infection, oral fungal infection, oropharyngitis fungal and tongue fungal infection.

^d—Leukopenia includes leukopenia and neutropenia.

^e—Pancytopenia includes pancytopenia and bicytopenia.

^f—Dysgeusia includes dysgeusia and taste disorder.

^g—Dry mouth includes dry mouth, lip dry, salivary hyposecretion and dry throat.

^h—Vomiting includes vomiting and retching.

ⁱ—Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness and gastrointestinal pain.

^j—Oesophageal disorder includes gastrooesophageal reflux disease, dysphagia and oesophagitis.

^k—Dry skin includes dry skin and xeroderma.

^l—Urinary tract infection includes urinary tract infection, cystitis and cystitis bacterial.

^m—Acute kidney injury includes blood creatinine increased, acute kidney injury, renal failure and blood urea increased.

ⁿ—Fatigue includes fatigue and asthenia.

^o—Oedema peripheral includes oedema peripheral, fluid retention and hypervolaemia.

[illegible]

	Pluvicto plus BSoC (N = 529)			BSoC (N = 205)		
Adverse drug reactions	All grades n (%)	Frequency category	Grades 3 to 4^b n (%)	All grades n (%)	Frequency category	Grades 3 to 4^b n (%)
Dry mouth ^g	208 (39.3%)	Very common	0	2 (1.0%)	Uncommon	0
Nausea	189 (35.7%)	Very common	7 (1.3%)	34 (16.6%)	Very common	1 (0.5%)
Constipation	107 (20.2%)	Very common	6 (1.1%)	23 (11.2%)	Very common	1 (0.5%)
Vomiting ^h	101 (19.1%)	Very common	5 (0.9%)	13 (6.3%)	Common	1 (0.5%)
Diarrhoea	101 (19.1%)	Very common	4 (0.8%)	6 (2.9%)	Common	1 (0.5%)
Abdominal pain ⁱ	61 (11.5%)	Very common	7 (1.3%)	13 (6.3%)	Common	1 (0.5%)
Oesophageal disorder ^j	18 (3.4%)	Common	1 (0.2%)	3 (1.5%)	Common	0
Stomatitis	9 (1.7%)	Common	1 (0.2%)	0		0
Skin and subcutaneous tissue disorders						
Dry skin ^k	8 (1.5%)	Common	0	2 (1.0%)	Uncommon	0
Renal and urinary disorders						
Urinary tract infection ^l	63 (11.9%)	Very common	20 (3.8%)	2 (1.0%)	Uncommon	1 (0.5%)
Acute kidney injury ^m	48 (9.1%)	Common	18 (3.4%)	12 (5.9%)	Common	6 (2.9%)
General disorders and administration site conditions						
Fatigue ⁿ	254 (48.0%)	Very common	35 (6.6%)	60 (29.3%)	Very common	5 (2.4%)
Decreased appetite	113 (21.4%)	Very common	10 (1.9%)	30 (14.6%)	Very common	1 (0.5%)
Weight decreased	58 (11.0%)	Very common	2 (0.4%)	20 (9.8%)	Common	1 (0.5%)
Oedema peripheral ^o	53 (10.0%)	Very Common	2 (0.4%)	14 (6.8%)	Common	2 (1.0%)
Pyrexia	37 (7.0%)	Common	2 (0.4%)	7 (3.4%)	Common	0

Abbreviation: BSoC, best standard of care.

^aNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

^bOnly includes Grades 3 to 4 adverse drug reactions, with the exception of pancytopenia and bone marrow failure. Grade 5 (fatal) pancytopenia was reported in 2 patients who received Pluvicto plus BSoC. Grade 5 (fatal) bone marrow failure was reported in 1 patient who received Pluvicto plus BSoC.

^cOral fungal infection includes oral candidiasis, candida infection, oral fungal infection, oropharyngitis fungal and tongue fungal infection.

^dLeukopenia includes leukopenia and neutropenia.

^ePancytopenia includes pancytopenia and bicytopenia.

^fDysgeusia includes dysgeusia and taste disorder.

^gDry mouth includes dry mouth, lip dry, salivary hyposecretion, and dry throat.

^hVomiting includes vomiting and retching.

ⁱAbdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, abdominal tenderness, and gastrointestinal pain.

^jOesophageal disorder includes gastrooesophageal reflux disease, dysphagia, and oesophagitis.

^kDry skin includes dry skin and xeroderma.

^lUrinary tract infection includes urinary tract infection, cystitis, and cystitis bacterial.

^mAcute kidney injury includes blood creatinine increased, acute kidney injury, renal failure, and blood urea increased.

ⁿFatigue includes fatigue and asthenia.

^oOedema peripheral includes oedema peripheral, fluid retention, and hypervolaemia.

Description of selected adverse reactions

Myelosuppression

In the VISION study, myelosuppression occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (all grades/grade ≥ 3): anaemia (31.9%/12.9%) versus (13.2%/4.9%); thrombocytopenia (17.2%/7.9%) versus (4.4%/1.0%); leukopenia (12.5%/2.5%) versus (2.0%/0.5%); lymphopenia (14.2%/7.8%) versus (3.9%/0.5%); neutropenia (8.5%/3.4%) versus (1.5%/0.5%); pancytopenia (1.5%/1.1%) versus (0%/0%) including two fatal events of pancytopenia in patients who received Pluvicto plus BSoC; bicytopenia (0.2%/0.2%) versus (0%/0%); and bone marrow failure (0.2%/0.2%) versus (0%/0%) including one fatal event of bone marrow failure in a patient who received Pluvicto plus BSoC.

Myelosuppression adverse reactions that led to permanent discontinuation in $\geq 0.5\%$ of patients who received Pluvicto plus BSoC included: anaemia (2.8%), thrombocytopenia (2.8%), leukopenia (1.3%), neutropenia (0.8%) and pancytopenia (0.6%). Myelosuppression adverse reactions that led to dose interruptions/dose reductions in $\geq 0.5\%$ of patients who received Pluvicto plus BSoC included: anaemia (5.1%/1.3%), thrombocytopenia (3.6%/1.9%), leukopenia (1.5%/0.6%) and neutropenia (0.8%/0.6%).

Renal toxicity

In the VISION study, renal toxicity occurred more frequently in patients who received Pluvicto plus BSoC compared to patients who received BSoC alone (all grades/grades 3 to 4): blood creatinine increased (5.7%/0.2%) versus (2.4%/0.5%); acute kidney injury (3.8%/3.2%) versus (3.9%/2.4%); renal failure (0.2%/0%) versus (0%/0%); and blood urea increased (0.2%/0%) versus (0%/0%).

Renal adverse reactions that led to permanent discontinuation in $\geq 0.2\%$ of patients who received Pluvicto plus BSoC included: blood creatinine increased (0.2%). Renal adverse reactions that led to dose interruptions/dose reductions in $\geq 0.2\%$ of patients who received Pluvicto plus BSoC included: blood creatinine increased (0.2%/0.4%) and acute kidney injury (0.2%/0%).

Second primary malignancies

Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations. In all cases it is necessary to ensure that the risks of the radiation are less than from the disease itself. As Pluvicto contributes to a patient's overall long-term radiation exposure, which is associated with an increased risk for cancer (see section 4.4), a potential risk of second primary malignancies cannot be ruled out for radiopharmaceuticals such as Pluvicto. At the time of the VISION primary analysis (cut-off date 27-Jan-2021), cases of squamous cell carcinoma (4 patients; 0.8%) and basal cell carcinoma, malignant melanoma and squamous cell carcinoma of the skin (1 patient each; 0.2% each) were reported in patients who received Pluvicto plus BSoC.

4.9 Overdose

In the event of administration of a radiation overdose with Pluvicto, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by frequent micturition or by forced diuresis and frequent bladder voiding. It might be helpful to estimate the effective dose that was applied.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Therapeutic radiopharmaceuticals, Other therapeutic radiopharmaceuticals, ATC code: V10XX05

Mechanism of action

The active moiety of Pluvicto is the radionuclide lutetium-177 which is linked to a small-molecule ligand that targets and binds with high affinity to PSMA, a transmembrane protein that is highly expressed in prostate cancer, including mCRPC. Upon the binding of Pluvicto to PSMA-expressing cancer cells, the beta-minus emission from lutetium-177 delivers therapeutic radiation to the targeted cell, as well as to surrounding cells, and induces DNA damage which can lead to cell death.

Pharmacodynamic effects

Vipivotide tetraxetan does not have any pharmacodynamic activity.

Clinical efficacy and safety

PSMAfore: PSMA-positive mCRPC previously treated with ARPI therapy

The efficacy of Pluvicto in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy was established in PSMAfore, a randomized, multicenter, open-label Phase III study. Four hundred and sixty-eight (N = 468) patients were randomized (1:1) to receive either Pluvicto 7,400 MBq (200 mCi) every 6 weeks for a total of 6 doses (N = 234) or a change in ARPI (N = 234).

Patients maintained castrate levels of serum/plasma testosterone by either medical castration or prior orchiectomy. Eligible patients were required to be candidates for ARPI switch, have PSMA-positive mCRPC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1, at least one metastatic lesion present on computed tomography (CT), magnetic resonance imaging (MRI) or bone scan imaging, and adequate renal, hepatic and hematological function.

Eligible patients were also required to have progressed only once on an ARPI (abiraterone acetate, enzalutamide, darolutamide, or apalutamide). Prior taxane-based chemotherapy was only allowed in the adjuvant or neoadjuvant setting greater than 12 months before enrollment. Patients with unstable symptomatic central nervous system metastases or symptomatic or clinically/radiologically impending spinal cord compression were not eligible for the study. Patients underwent a gallium (⁶⁸Ga) gozetotide positron emission tomography (PET) scan to evaluate PSMA expression in lesions defined by central read criteria. Eligible patients were required to have PSMA-positive mCRPC defined as having at least one tumor lesion with gallium (⁶⁸Ga) gozetotide uptake greater than in normal liver. Patients were considered ineligible if any intraprostatic lesion or any one lesion larger than size criteria [organs > 1 cm in longest diameter, lymph nodes ≥ 2.5 cm in short axis, bones (soft tissue component) ≥ 1 cm in longest diameter] had gallium (⁶⁸Ga) gozetotide uptake less than or equal to uptake in normal liver.

Supportive care administered at the physician's discretion included: bone-targeted agents including zoledronic acid, denosumab, or other bisphosphonates; androgen deprivation therapy (ADT); palliative radiotherapy. Patients randomized to the change in ARPI arm were allowed to cross over to receive Pluvicto upon radiographic disease progression confirmed by blinded independent central review (BICR) or continue to receive any other therapy at the physician's discretion.

The primary efficacy endpoint was radiographic progression-free survival (rPFS) as determined by BICR per Prostate Cancer Working Group 3 (PCWG3) criteria. The key secondary efficacy endpoint was overall survival (OS). Additional efficacy endpoints were time to first symptomatic skeletal event

(SSE), PSA50 response, overall response rate (ORR), and an updated rPFS analysis at the time of third interim OS analysis.

Demographic and baseline disease characteristics were balanced between the treatment arms. The median age was 72 years (range: 43 to 94 years); 91% White; 2.6% Black or African American; 0.6% Asian; 99% had ECOG PS0-1. Randomization was stratified by setting of prior ARPI use (castration-resistant prostate cancer (CRPC) vs. hormone-sensitive prostate cancer (HSPC)) and by symptomatology (asymptomatic or mildly symptomatic vs. symptomatic (score >3 on item 3 of the Brief Pain Inventory-Short Form (BPI-SF) questionnaire)).


Efficacy results for PSMAfore are presented in Table 4 and Figure 1. At the primary analysis (data cut-off (DCO) date: 02-Oct-2022), treatment with Pluvicto demonstrated a statistically significant improvement in rPFS by BICR compared to a change in ARPI therapy. There was an estimated 59% risk reduction of radiographic disease progression or death. An updated analysis of rPFS was conducted at the time of the third interim OS analysis (DCO date: 27-Feb-2024) and the results were consistent with the primary analysis. The final analysis of OS (DCO date: 01-Jan-2025) was conducted after the occurrence of 299 deaths without accounting for crossover, following the intent-to-treat (ITT) principle.

Table 4 Efficacy results in PSMAfore

<u>Efficacy parameters</u>	<u>Pluvicto</u>	<u>Change in ARPI</u>
Primary efficacy endpoints		
<u>Radiographic progression-free survival (rPFS)^a</u>	<u>N = 233</u>	<u>N = 234</u>
<u>Events (progression or death), n (%)</u>	<u>60 (25.8%)</u>	<u>106 (45.3%)</u>
<u>Radiographic progressions, n (%)</u>	<u>53 (22.7%)</u>	<u>99 (42.3%)</u>
<u>Deaths, n (%)</u>	<u>7 (3.0%)</u>	<u>7 (3.0%)</u>
<u>Hazard ratio (95% CI)^b</u>	<u>0.41 (0.29, 0.56)</u>	
<u>P-value^c</u>	<u><0.001</u>	
<u>Median, months (95% CI)^d</u>	<u>9.3 (6.8, NE)</u>	<u>5.6 (4.0, 6.0)</u>
<u>Updated median, months (95% CI)^e</u>	<u>11.6 (9.3, 14.2)</u>	<u>5.6 (4.2, 6.0)</u>
<u>Key secondary efficacy endpoints</u>		
<u>Overall survival (OS)^f</u>	<u>N = 234</u>	<u>N = 234</u>
<u>Deaths, n (%)</u>	<u>142 (60.7%)</u>	<u>112157 (67.1%)</u>
<u>Median, months (95% CI)^d</u>	<u>24.5 (19.5, 28.9)</u>	<u>23.1 (19.6, 25.5)</u>
<u>Hazard ratio (95% CI)^b</u>	<u>0.91 (0.72, 1.14)</u>	
<u>P-value^c</u>	<u>0.20</u>	
<u>Additional secondary efficacy endpoints^g</u>		
<u>Time to symptomatic skeletal event (SSE)</u>	<u>N = 234</u>	<u>N = 234</u>
<u>Events (SSE or death), n (%)</u>	<u>31 (13.2%)</u>	<u>68 (29.1%)</u>
<u>SSEs, n (%)</u>	<u>27 (11.5%)</u>	<u>63 (26.9%)</u>
<u>Deaths, n (%)</u>	<u>4 (1.7%)</u>	<u>5 (2.1%)</u>
<u>Median, months (95% CI)^d</u>	<u>NE</u>	<u>18.0 (14.3, NE)</u>
<u>Hazard ratio (95% CI)^b</u>	<u>0.41 (0.26, 0.63)</u>	
<u>PSA50 response</u>	<u>N = 220</u>	<u>N = 226</u>
<u>PSA50 response rate, n (%)</u>	<u>113 (51.4%)</u>	<u>39 (17.3%)</u>
<u>Best overall response (BOR)</u>		
<u>Patients with measurable disease at baseline^{gh}</u>	<u>N = 72</u>	<u>N = 72</u>
<u>Complete response (CR), n (%)</u>	<u>15 (20.8%)</u>	<u>2 (2.8%)</u>
<u>Partial response (PR), n (%)</u>	<u>20 (27.8%)</u>	<u>8 (11.1%)</u>
<u>Stable disease (SD), n (%)</u>	<u>21 (29.2%)</u>	<u>30 (41.7%)</u>
<u>Progressive disease (PD), n (%)</u>	<u>14 (19.4%)</u>	<u>27 (37.5%)</u>
<u>Unknown, n (%)</u>	<u>2 (2.8%)</u>	<u>5 (6.9%)</u>
<u>Overall response rate (ORR)^{g,h,i,j}</u>	<u>35 (48.6%)</u>	<u>10 (13.9%)</u>

Efficacy parameters	Pluvicto	Change in ARPI
Abbreviations: CI, confidence interval; NE, not estimable; BICR, blinded independent central review; PCWG3, prostate cancer working group 3; RECIST, response evaluation criteria in solid tumors.		
^a By BICR per PCWG3 criteria. Based on data cut-off (DCO) date 02-Oct-2022.		
^b Hazard ratio based on the stratified Cox PH model. Hazard ratio <1 favors Pluvicto.		
^c Stratified log-rank test one-sided p-value.		
^d Based on Kaplan-Meier estimate.		
^e Median from third interim OS analysis based on 468 patients (234 Pluvicto arm, 234 control arm). Compared to the primary analysis, the median study duration from randomization to DCO increased from 7.3 months to 24.1 months.		
^f DCO date: 01-Jan-2025.		
^g DCO date for all additional secondary efficacy endpoints is 27-Feb-2024.		
^h Responses are based on soft tissue and bone lesion assessment. DCO date 27-Feb-2024.		
ⁱ By BICR per RECIST v1.1.		
^j ORR: CR+PR. Confirmed response for CR and PR.		

Figure 14 Kaplan-Meier plot of BICR-assessed radiographic progression-free survival (rPFS) in PSMAfore



Stratified log-rank test and stratified Cox model using strata per Interactive Response Technology (IRT) defined by setting of prior ARPI use and by symptomatology.
n/N: Number of events/number of patients in treatment arm.

Based on 27-Feb-2024 DCO, FACT-P total score showed an estimated 39% risk reduction of worsening from baseline, clinical progression or death based on hazard ratios in favor of Pluvicto, indicating patient stabilization and delay in time to deterioration while on Pluvicto treatment. Specifically, time to worsening of the FACT-P total score was delayed by 3.2 months for Pluvicto with a median time to deterioration of 7.5 months (95% CI: 6.1, 8.5) compared to 4.3 months (95% CI: 3.5, 4.5) in the change in ARPI arm.

BPI-SF pain intensity scale showed an estimated 28% risk reduction of worsening from baseline, clinical progression or death based on hazard ratios in favor of Pluvicto, indicating patient stabilization and less pain while on Pluvicto treatment. Specifically, time to worsening of the BPI-SF pain intensity scale was delayed by 1.3 months for Pluvicto with a median time to deterioration of 5.0 months (95% CI: 4.4, 6.8) compared to 3.7 months (95% CI: 3.1, 4.4) in the change in ARPI arm.

VISION: PSMA-positive mCRPC previously treated with ARPI therapy and taxane-based chemotherapy

VISION

The efficacy of Pluvicto in patients with progressive, PSMA-positive mCRPC previously treated with ARPI therapy and taxane-based chemotherapy was evaluated in VISION, a randomised, multicentre, open-label phase III study. Eight hundred and thirty-one (N=831) adult patients were randomised (2:1) to receive either Pluvicto 7 400 MBq every 6 weeks for up to a total of 6 doses plus best standard of

care (BSoC) (N=551) or BSoC alone (N=280). Patients who received 4 doses of Pluvicto were reassessed for evidence of response, signs of residual disease, and tolerability and could receive up to 2 additional doses per physician's discretion.

Patients maintained castrate levels of serum/plasma testosterone by either medical castration or prior orchiectomy. To maintain castration status, all patients continued to receive a GnRH analogue or had prior bilateral orchiectomy. Eligible patients were required to have progressive, PSMA-positive mCRPC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2, at least one metastatic lesion present on computed tomography (CT), magnetic resonance imaging (MRI) or bone scan imaging, and adequate renal, hepatic and haematological function.

Eligible patients were also required to have received at least one ARPI-pathway inhibitor, such as abiraterone acetate or enzalutamide, and 1 or 2 prior taxane-based chemotherapy regimens (with a regimen defined as a minimum exposure of 2 cycles of a taxane). Patients treated with only 1 prior taxane-based chemotherapy regimen were eligible if the patient was unwilling or the physician deemed the patient unsuitable to receive a second regimen. Patients with unstable symptomatic central nervous system metastases or symptomatic or clinically/radiologically impending spinal cord compression were not eligible for the study. Patients underwent a gallium (^{68}Ga) gozetotide positron emission tomography (PET) scan to evaluate PSMA expression in lesions defined by central read criteria. Eligible patients were required to have PSMA-positive mCRPC defined as having at least one tumour lesion with gallium (^{68}Ga) gozetotide uptake greater than in normal liver. Patients were excluded if any lesions exceeding size criteria in short axis (organs ≥ 1 cm, lymph nodes ≥ 2.5 cm, bones [soft-tissue component] ≥ 1 cm) had uptake less than or equal to uptake in normal liver.

BSoC administered at the physician's discretion included: supportive measures including pain management, hydration, blood transfusions, etc.; ketoconazole; radiation therapy (including seeded form or any external beam radiotherapy [including stereotactic body radiotherapy and palliative external beam]) to localised prostate cancer targets; bone-targeted agents including zoledronic acid, denosumab and any bisphosphonates; androgen reducing agents ADT including GnRH analogues, any corticosteroid, and 5-alpha reductases; ARPIs-pathway inhibitors. BSoC excluded investigational agents, cytotoxic chemotherapy, immunotherapy, other systemic radioisotopes and hemi-body radiotherapy treatment.

Patients continued randomised treatment until evidence of tumour progression (based on investigator assessment per Prostate Cancer Working Group 3 [PCWG3] criteria), unacceptable toxicity, use of prohibited treatment, non-compliance or withdrawal, or lack of clinical benefit.

The primary efficacy endpoints were overall survival (OS) and radiographic progression-free survival (rPFS) as determined by blinded independent central review (BICR) per PCWG3 criteria. Among the secondary efficacy endpoints were overall response rate (ORR) as determined by BICR per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and time to first symptomatic skeletal event (SSE) defined as first new symptomatic pathological bone fracture, spinal cord compression, tumour-related orthopaedic surgical intervention, requirement for radiation therapy to relieve bone pain, or death from any cause, whichever occurred first. Radiographic imaging for tumour assessment (CT with contrast/MRI imaging and bone scan) was done every 8 weeks (± 4 days) after the first dose for the first 24 weeks (independent of dose delays), then every 12 weeks (± 4 days).

Demographic and baseline disease characteristics were balanced between the treatment arms. The median age was 71 years (range: 40 to 94 years); 86.8% White; 6.6% Black or African American; 2.4% Asian; 92.4% had ECOG PS0-1; 7.6% had ECOG PS2. Randomisation was stratified by baseline lactate dehydrogenase (LDH ≤ 260 IU/L vs. >260 IU/L), presence of liver metastases (yes vs. no), ECOG PS score (0 or 1 vs. 2), and inclusion of an ARPI pathway inhibitor as part of BSoC at the time of randomisation (yes vs. no). At randomisation, all patients (100.0%) had received at least one prior taxane-based chemotherapy regimen and 41.2% of patients had received two; 97.1% of patients had

received docetaxel and 38.0% of patients had received cabazitaxel. At randomisation, 51.3% of patients had received one prior ARPI-pathway-inhibitor, 41.0% of patients had received 2, and 7.7% of patients had received 3 or more. During the randomised treatment period, 52.6% of patients in the Pluvicto plus BSoC arm and 67.8% of patients in the BSoC alone arm received at least one ARPI-pathway-inhibitor.

Efficacy results for VISION are presented in Table 3-5 and Figures 4-2 and 23. The final analyses of OS and rPFS were event-driven and conducted after the occurrence of 530 deaths and 347 events, respectively.

Table 35 Efficacy results in VISION

Efficacy parameters	Pluvicto plus BsoC	BSoC
Alternate primary efficacy endpoints		
Overall survival (OS) ^a	N=551	N=280
Deaths, n (%)	343 (62.3%)	187 (66.8%)
Median, months (95% CI) ^b	15.3 (14.2; 16.9)	11.3 (9.8; 13.5)
Hazard ratio (95% CI) ^c	0.62 (0.52; 0.74)	
P-value ^d	<0.001	
Radiographic progression-free survival (rPFS) ^{e,f}	N=385	N=196
Events (progression or death), n (%)	254 (66.0%)	93 (47.4%)
Radiographic progressions, n (%)	171 (44.4%)	59 (30.1%)
Deaths, n (%)	83 (21.6%)	34 (17.3%)
Median, months (99.2% CI) ^b	8.7 (7.9; 10.8)	3.4 (2.4; 4.0)
Hazard ratio (99.2% CI) ^c	0.40 (0.29; 0.57)	
P-value ^d	<0.001	
Secondary efficacy endpoints		
Time to first symptomatic skeletal event (SSE) ^f	N=385	N=196
Events (SSE or death), n (%)	256 (66.5%)	137 (69.9%)
SSEs, n (%)	60 (15.6%)	34 (17.3%)
Deaths, n (%)	196 (50.9%)	103 (52.6%)
Median, months (95% CI) ^b	11.5 (10.3; 13.2)	6.8 (5.2; 8.5)
Hazard ratio (95% CI) ^c	0.50 (0.40; 0.62)	
P-value ^g	<0.001	
Best overall response (BOR)		
Patients with evaluable disease at baseline	N=319	N=120
Complete response (CR), n (%)	18 (5.6%)	0 (0%)
Partial response (PR), n (%)	77 (24.1%)	2 (1.7%)
Overall response rate (ORR) ^{h,i}	95 (29.8%)	2 (1.7%)
P-value ^j	<0.001	
Duration of response (DOR) ^h		
Median, months (95% CI) ^b	9.8 (9.1; 11.7)	10.6 (NE; NE) ^k

BSoC: Best standard of care; CI: Confidence interval; NE: Not evaluable; BICR: Blinded independent central review; PCWG3: Prostate Cancer Working Group 3; RECIST: Response Evaluation Criteria in Solid Tumors.

^a Analysed on an intent-to-treat (ITT) basis in all randomised patients.

^b Based on Kaplan-Meier estimate.

^c Hazard ratio based on the stratified Cox PH model. Hazard ratio <1 favours Pluvicto plus BSoC.

^d Stratified log-rank test one-sided p-value.

^e By BICR per PCWG3 criteria. The primary analysis of rPFS included censoring of patients who had ≥2 consecutive missed tumour assessments immediately prior to progression or death. Results for rPFS with and without censoring for missed assessments were consistent.

^f Analysed on an ITT basis in all patients randomised on or after 05-Mar-2019, when actions were implemented to mitigate early drop-out from BSoC arm.

^g Stratified log-rank test two-sided p-value.


^h By BICR per RECIST v1.1.

ⁱ ORR: CR+PR. Confirmed response for CR and PR.

^j Stratified Wald's Chi-square test two-sided p-value.


^k Median DOR in the BSoC only arm was not reliable since only 1 of the 2 patients who responded had RECIST v1.1 radiographic progression or death.

Figure 42 Kaplan-Meier plot of OS in VISION



Stratified log-rank test and stratified Cox model using strata per Interactive Response Technology (IRT) defined by LDH level, presence of liver metastases, ECOG score and inclusion of an ARPI-pathway-inhibitor in BSoC at time of randomisation.
n/N: Number of events/number of patients in treatment arm.

Figure 23 Kaplan-Meier plot of BICR-assessed rPFS in VISION



Stratified log-rank test and stratified Cox model using strata per IRT defined by LDH level, presence of liver metastases, ECOG score and inclusion of an ARPI pathway inhibitor in BSoC at time of randomisation.
n/N: Number of events/number of patients in treatment arm.

5.2 Pharmacokinetic properties

The pharmacokinetics of lutetium (^{177}Lu) vipivotide tetraxetan have been characterised in 30 patients in the phase III VISION sub-study.

Absorption

Pluvicto is administered intravenously and is immediately and completely bioavailable.

The geometric mean blood exposure (area under the curve [AUC_{inf}]) for lutetium (^{177}Lu) vipivotide tetraxetan at the recommended dose is 52.3 ng.h/mL (geometric mean coefficient of variation [CV] 31.4%). The geometric mean maximum blood concentration (C_{max}) for lutetium (^{177}Lu) vipivotide tetraxetan at the recommended dose is 6.58 ng/mL (CV 43.5%).

Distribution

The geometric mean volume of distribution (V_z) for lutetium (^{177}Lu) vipivotide tetraxetan is 123 L (CV 78.1%).

Vipivotide tetraxetan and non-radioactive lutetium (^{175}Lu) vipivotide tetraxetan are each 60% to 70% bound to human plasma proteins.

Organ uptake

The biodistribution of lutetium (^{177}Lu) vipivotide tetraxetan shows primary uptake in lacrimal glands, salivary glands, kidneys, urinary bladder wall, liver, small intestine and large intestine (left and right colon).

Elimination

The geometric mean clearance (CL) for lutetium (^{177}Lu) vipivotide tetraxetan is 2.04 L/h (CV 31.5%).

Lutetium (^{177}Lu) vipivotide tetraxetan is primarily eliminated renally.

Half-life

Pluvicto shows a bi-exponential elimination with a geometric mean terminal elimination half-life ($t_{1/2}$) of 41.6 hours (CV 68.8%).

Biotransformation

Lutetium (^{177}Lu) vipivotide tetraxetan does not undergo hepatic or renal metabolism.

In vitro evaluation of drug interaction potential

CYP450 enzymes

Vipivotide tetraxetan is not a substrate of cytochrome P450 (CYP450) enzymes. It does not induce cytochrome P450 (CYP) 1A2, 2B6 or 3A4, and it does not inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A4/5 *in vitro*.

Transporters

Vipivotide tetraxetan is not a substrate of BCRP, P-gp, MATE1, MATE2-K, OAT1, OAT3 or OCT2, and it is not an inhibitor of BCRP, P-gp, BSEP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 or OCT2 *in vitro*.

Special populations

Effects of age and body weight

No clinically significant effects on the pharmacokinetic parameters of lutetium (^{177}Lu) vipivotide tetraxetan were identified for the following covariates assessed in 30 patients in the phase III VISION sub-study: age (median: 67 years; range: 52 to 80 years) and body weight (median: 88.8 kg; range: 63.8 to 143.0 kg).

Renal impairment

Exposure (AUC) of lutetium (^{177}Lu) vipivotide tetraxetan increased by 20% in patients with mild renal impairment compared to normal renal function. Kidney dosimetry half-life also increased in patients with mild renal impairment compared to normal renal function, 51 hours vs. 37 hours, respectively. Patients with mild or moderate renal impairment may be at greater risk of toxicity (see section 4.4). No pharmacokinetic data are available for patients with moderate to severe renal impairment with baseline CL_{Cr} <50 mL/min or end-stage renal disease.

5.3 Preclinical safety data

No toxicological effects were observed in safety pharmacology or single-dose toxicity studies in rats and minipigs administered a non-radioactive formulation containing vipivotide tetraxetan and lutetium (^{175}Lu) vipivotide tetraxetan, or in repeat-dose toxicity studies in rats administered vipivotide tetraxetan.

Carcinogenicity and mutagenicity

Mutagenicity and long-term carcinogenicity studies have not been carried out with lutetium (^{177}Lu) vipivotide tetraxetan; however, radiation is a carcinogen and mutagen.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Acetic acid
Sodium acetate
Gentisic acid
Sodium ascorbate
Pentetic acid
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in sections 4.2 and 10.

6.3 Special precautions for storage

Store below 30°C.
Do not freeze.
Store in the original package in order to protect from ionising radiation (lead shielding).

Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive materials.

6.4 Nature and contents of container

Clear, colourless type I glass vial, closed with a bromobutyl rubber stopper and aluminium seal.

Each vial contains a volume of solution that can range from 7.5 mL to 12.5 mL corresponding to a radioactivity of 7 400 MBq $\pm$ 10% at the date and time of administration.

The vial is enclosed within a lead container for protective shielding.

6.5 Special precautions for disposal and other handling

General warning

Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.

Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.

For instructions on preparation of the medicinal product before administration, see section 10.

If at any time in the preparation of this medicinal product the integrity of the lead container or the vial is compromised it should not be used.

Administration procedures should be carried out in a way to minimise risk of contamination of the medicinal product and irradiation of the operators. Adequate shielding is mandatory.

The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with national regulations must therefore be taken.

This preparation is likely to result in a relatively high radiation dose to most patients. The administration of Pluvicto may result in significant environmental hazard. This may be of concern to the immediate family of those individuals undergoing treatment or the general public depending on the level of activity administered. Suitable precautions in accordance with national regulations should be taken concerning the activity eliminated by the patients in order to avoid any contaminations.

Lutetium-177 for Pluvicto may be prepared using two different sources of stable nuclides (either lutetium-176 or ytterbium-176). Lutetium-177 for Pluvicto prepared using the stable isotope lutetium-176 ("carrier added") requires special attention with regard to waste management due to the presence of the long-lived metastable lutetium-177 (^{177m}Lu) impurity with a half-life of 160.4 days. Lutetium-177 for Pluvicto is prepared using ytterbium-176 ("non-carrier added") unless otherwise communicated on the product batch release certificate. The user must consult the product batch release certificate provided before using Pluvicto to ensure appropriate waste management.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. PRODUCT REGISTRATION HOLDER

Novartis Corporation (M) Sdn. Bhd.
Level 18, Imazium,
No. 8, Jalan SS21/37,
Damansara Uptown,
47400 Petaling Jaya, Selangor

8. DATE OF REVISION OF THE TEXT

Information Issued: ~~EU 16-Jun-2025~~CDS 7-Apr-2025

Date of Revision: Nov 2025~~Aug 2025~~

Commented [AH10]: Most likely needs updating

Commented [LK11R10]: yes, missed this out.

9. DOSIMETRY

Radiation dose to specific organs, which may not be the target organ of therapy, can be influenced significantly by pathophysiological changes induced by the disease process. This should be taken into consideration when using the following information.

Dosimetry of lutetium (^{177}Lu) vipivotide tetraxetan was collected in 29 patients in the phase III VISION sub-study, in order to calculate whole body and organ radiation dosimetry. The mean and standard deviation (SD) of the estimated absorbed doses to different organs for adult patients receiving Pluvicto are shown in Table 46. The organs with the highest absorbed doses are lacrimal glands and salivary glands.

The maximum penetration of lutetium-177 in tissue is approximately 2 mm and the mean penetration is 0.67 mm.

Table 46 Estimated absorbed dose^a for Pluvicto in the VISION sub-study

Organ	Absorbed dose per unit activity (mGy/MBq) (N=29)		Calculated absorbed dose for 7 400 MBq administration (Gy)		Calculated absorbed dose for 6 x 7 400 MBq (44 400 MBq cumulative activity) (Gy)	
	Mean	SD	Mean	SD	Mean	SD
Adrenals	0.033	0.025	0.24	0.19	1.5	1.1
Brain	0.007	0.005	0.049	0.035	0.30	0.22
Eyes	0.022	0.024	0.16	0.18	0.99	1.1
Gallbladder wall	0.028	0.026	0.20	0.19	1.2	1.1
Heart wall	0.17	0.12	1.2	0.83	7.8	5.2
Kidneys	0.43	0.16	3.1	1.2	19	7.3
Lacrimal glands	2.1	0.47	15	3.4	92	21
Left colon	0.58	0.14	4.1	1.0	26	6.0
Liver	0.090	0.044	0.64	0.32	4.0	2.0
Lungs	0.11	0.11	0.76	0.81	4.7	4.9
Oesophagus	0.025	0.026	0.18	0.19	1.1	1.1
Osteogenic cells	0.036	0.028	0.26	0.21	1.6	1.3
Pancreas	0.027	0.026	0.19	0.19	1.2	1.1
Prostate	0.027	0.026	0.19	0.19	1.2	1.1
Red marrow	0.035	0.020	0.25	0.15	1.5	0.90
Rectum	0.56	0.14	4.0	1.1	25	6.2
Right colon	0.32	0.078	2.3	0.58	14	3.4
Salivary glands	0.63	0.36	4.5	2.6	28	16
Small intestine	0.071	0.031	0.50	0.23	3.1	1.4
Spleen	0.067	0.027	0.48	0.20	3.0	1.2
Stomach wall	0.025	0.026	0.18	0.19	1.1	1.1
Testes	0.023	0.025	0.16	0.18	1.0	1.1
Thymus	0.025	0.026	0.18	0.19	1.1	1.1
Thyroid	0.26	0.37	1.8	2.7	11	16
Total body	0.037	0.027	0.27	0.20	1.6	1.2
Urinary bladder wall	0.32	0.025	2.3	0.19	14	1.1
Effective dose ^b	0.120	0.043	0.886	0.315	5.319	1.892
	mSv/MBq	mSv/MBq	Sv	Sv	Sv	Sv

^a Absorbed dose estimates were derived using OLINDA v2.2. Values have been calculated based on dosimetry estimates at full precision and rounded to relevant digits.

^b Derived according to ICRP Publication 103.

10. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

The user must consult the product batch release certificate provided before using Pluvicto to ensure appropriate waste management (see section 6.5).

Withdrawals should be performed under aseptic conditions. The vials must not be opened before disinfecting the stopper, the solution should be withdrawn via the stopper using a single-dose syringe fitted with suitable protective shielding and a disposable sterile needle or using an authorised automated application system.

Preparation instructions

- Use aseptic technique and radiation shielding when handling or administering Pluvicto, using tongs as needed to minimise radiation exposure.
- Visually inspect the product under a shielded screen for particulate matter and discolouration prior to administration. Discard the vial if particulates and/or discolouration are present.
- Do not inject the Pluvicto solution directly into any other intravenous solution.
- Confirm the amount of radioactivity delivered to the patient with an appropriately calibrated dose calibrator prior to and after each Pluvicto administration.

Intravenous methods of administration

Instructions for the syringe method

- Withdraw an appropriate volume of Pluvicto solution to deliver the desired radioactivity by using a disposable syringe fitted with a syringe shield and a disposable sterile needle that is 9 cm, 18 gauge (long needle). To aid the withdrawal of the solution, a filtered 2.5 cm, 20 gauge needle (short venting needle) can be used to reduce the resistance from the pressurised vial. Ensure that the short needle does not touch the Pluvicto solution in the vial.
- If using a syringe pump, fit the syringe into the shielded pump and include a 3-way stopcock valve between the syringe and an intravenous catheter primed with sterile sodium chloride 9 mg/mL (0.9%) solution for injection and used for Pluvicto administration to the patient.
- Administer Pluvicto to the patient by slow intravenous push within approximately 1 to 10 minutes (either with a syringe pump or manually without a syringe pump) via an intravenous catheter that is primed with sterile sodium chloride 9 mg/mL (0.9%) solution for injection and that is used exclusively for Pluvicto administration to the patient.
- When the desired Pluvicto radioactivity has been delivered, stop the syringe pump and then change the position of the 3-way stopcock valve to flush the syringe with 25 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection. Restart the syringe pump.
- After the flush of the syringe has been completed, perform an intravenous flush of ≥ 10 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection through the intravenous catheter to the patient.

Instructions for the gravity method

- Insert a 2.5 cm, 20 gauge needle (short needle) into the Pluvicto vial and connect via a catheter to 500 mL sterile sodium chloride 9 mg/mL (0.9%) solution for injection (used to transport the Pluvicto solution during the infusion). Ensure that the short needle does not touch the Pluvicto solution in the vial and do not connect the short needle directly to the patient. Do not allow the sterile sodium chloride 9 mg/mL (0.9%) solution for injection to flow into the Pluvicto vial prior to the initiation of the Pluvicto infusion and do not inject the Pluvicto solution directly into the sterile sodium chloride 9 mg/mL (0.9%) solution for injection.
- Insert a second needle that is 9 cm, 18 gauge (long needle) into the Pluvicto vial, ensuring that the long needle touches and is secured to the bottom of the Pluvicto vial during the entire infusion. Connect the long needle to the patient by an intravenous catheter that is primed with

sterile sodium chloride 9 mg/mL (0.9%) solution for injection and that is used exclusively for the Pluvicto infusion into the patient.

- Use a clamp or an infusion pump to regulate the flow of the sterile sodium chloride 9 mg/mL (0.9%) solution for injection via the short needle into the Pluvicto vial (the sterile sodium chloride 9 mg/mL (0.9%) solution for injection entering the vial through the short needle will carry the Pluvicto solution from the vial to the patient via the intravenous catheter connected to the long needle within approximately 30 minutes).
- During the infusion, ensure that the level of solution in the Pluvicto vial remains constant.
- Disconnect the vial from the long needle line and clamp the sterile sodium chloride 9 mg/mL (0.9%) solution for injection line once the level of radioactivity is stable for at least five minutes.
- Follow the infusion with an intravenous flush of ≥ 10 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection through the intravenous catheter to the patient.

Instructions for the peristaltic pump method

- Insert a filtered 2.5 cm, 20 gauge needle (short venting needle) into the Pluvicto vial. Ensure that the short needle does not touch the Pluvicto solution in the vial and do not connect the short needle directly to the patient or to the peristaltic pump.
- Insert a second needle that is 9 cm, 18 gauge (long needle) into the Pluvicto vial, ensuring that the long needle touches and is secured to the bottom of the Pluvicto vial during the entire infusion. Connect the long needle and a sterile sodium chloride 9 mg/mL (0.9%) solution for injection to a 3-way stopcock valve via appropriate tubing.
- Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic pump according to manufacturer's instructions.
- Prime the line by opening the 3-way stopcock valve and pumping the Pluvicto solution through the tubing until it reaches the exit of the valve.
- Prime the intravenous catheter which will be connected to the patient by opening the 3-way stopcock valve to the sterile sodium chloride 9 mg/mL (0.9%) solution for injection and pumping the sterile sodium chloride 9 mg/mL (0.9%) solution for injection until it exits the end of the catheter tubing.
- Connect the primed intravenous catheter to the patient and set the 3-way stopcock valve such that the Pluvicto solution is in line with the peristaltic pump.
- Infuse an appropriate volume of Pluvicto solution at approximately 25 mL/h to deliver the desired radioactivity.
- When the desired Pluvicto radioactivity has been delivered, stop the peristaltic pump and then change the position of the 3-way stopcock valve so that the peristaltic pump is in line with the sterile sodium chloride 9 mg/mL (0.9%) solution for injection. Restart the peristaltic pump and infuse an intravenous flush of ≥ 10 mL of sterile sodium chloride 9 mg/mL (0.9%) solution for injection through the intravenous catheter to the patient.

Quality control

The solution should be visually inspected for damage and contamination before use, and only clear solutions free of visible particles should be used. The visual inspection of the solution should be performed under a shielded screen for radioprotection purposes. The vial must not be opened.

If at any time in the preparation of this medicinal product the integrity of the lead container or the vial is compromised, it should not be used.

The amount of radioactivity in the vial must be measured prior to administration using a suitable radioactivity calibration system in order to confirm that the actual amount of radioactivity to be administered is equal to the planned amount at the administration time.